Journal of Cancer Research and Therapeutics

REVIEW ARTICLE
Year
: 2021  |  Volume : 17  |  Issue : 4  |  Page : 819--833

Autoantibodies in the diagnosis, prognosis, and prediction of colorectal cancer


Roshan Niloofa1, M Ishan De Zoysa2, L Suranjith Seneviratne1 
1 Department of Zoology and Environmental Sciences, Faculty of Science, University of Colombo, Colombo, Sri Lanka
2 Department of Surgery, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka

Correspondence Address:
Roshan Niloofa
Department of Zoology and Environmental Sciences, Faculty of Science, University of Colombo, Colombo
Sri Lanka

Colorectal cancer (CRC) is the second-most commonly diagnosed cancer worldwide. Early diagnosis improves prognosis and long-term outcomes. Several studies have found tumor-associated autoantibodies in CRC patients. We aimed to provide an overview on CRC-associated autoantibodies and their reported diagnostic, prognostic, and predictive performance when used singly or in combination. We systematically reviewed studies on CRC-related autoantibodies published till March 2018 and critically analyzed the role of these autoantibodies in CRC. In general, autoantibodies were of low sensitivity when tested individually and the diagnostic characteristics improved when tested in combination. Autoantibodies against CCD83, carcinoembryonic antigen, MAPKAPK3, RPH 3AL, SEC61b, and SPAG9 showed high sensitivity and specificity when tested alone. When tested in combination, autoantibodies against three antigens (PIM1, MAPKAPK3, and ACVR2B) showed high sensitivity and specificity. So far, most CRC-associated autoantibodies have been evaluated in single or in a small number of studies. In contrast, anti-p53 antibodies have been studied in a larger number of CRC studies, but, so far, none of them have high diagnostic characteristics. CRC-associated autoantibodies are detectable from the early stages of malignancy, pointing to their possible use in the early detection of CRC. Some studies suggest that CRC-associated autoantibodies may be a guide to prognosis in CRC.


How to cite this article:
Niloofa R, De Zoysa M I, Seneviratne L S. Autoantibodies in the diagnosis, prognosis, and prediction of colorectal cancer.J Can Res Ther 2021;17:819-833


How to cite this URL:
Niloofa R, De Zoysa M I, Seneviratne L S. Autoantibodies in the diagnosis, prognosis, and prediction of colorectal cancer. J Can Res Ther [serial online] 2021 [cited 2021 Nov 28 ];17:819-833
Available from: https://www.cancerjournal.net/article.asp?issn=0973-1482;year=2021;volume=17;issue=4;spage=819;epage=833;aulast=Niloofa;type=0